Developer docs
API playgroundTry for free, no card

Search company profiles

Thor Medical

Full company profile

uuid0002gk4

Namestring
Thor Medical
Legal namestring
Thor Medical ASA
Websiteurl
thormedical.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Thor Medical ASA is a Norwegian biopharmaceutical company founded in 2017 and listed on the Oslo Stock Exchange (ticker TRMED) that produces alpha-emitting radioisotopes — Thorium-228, Radium-224 and Lead-212 — for use in targeted alpha therapy for haematological and other cancers. Its core technology is a proprietary, trade-secret-protected separation process that extracts naturally occurring radioactive decay products from thorium-232 without requiring irradiation in nuclear reactors or charged particle accelerators, and uses a closed-loop reprocessing system that reuses all chemicals and radioactive materials while producing minimal waste. The platform effectively turns a single source material (thorium, with a 14 billion year half-life) into multiple medically relevant alpha emitters, two of which — Ra-224 and Pb-212 — are leading candidates for next-generation cancer therapy because alpha particles destroy cancer cells within less than 0.1 mm of range, enabling highly selective treatment of micrometastases.

The company operates a pilot production facility at Herøya Industrial Park in Norway, which has been producing alpha-emitting isotopes since 2024 and supplying them for research and early customer deliveries since 2025. Its first commercial-scale facility, AlphaOne, reached mechanical completion on time and on budget in April 2026 and is targeting production start in Q3 2026, with a planned 40% capacity expansion financed by a June 2025 capital raise. Thor Medical sells isotopes directly to radiopharmaceutical developers and biotech companies through multi-year master supply agreements — AdvanCell (NOK 150M over 5 years, expanded August 2025), RadioMedix (5-year supply from 2026), Nuclithera and Node Pharma — and to radiopharmaceutical CDMOs and integrated service providers such as Minerva Imaging and Eckert & Ziegler SE, which act as channel partners embedding Thor Medical's isotopes within broader development and manufacturing platforms. Customer segments are vertically aligned (radiopharmaceutical developers, CDMOs, and research/early-stage clinical developers), with the addressable radiotherapeutics market expected to reach approximately USD 20 billion by 2030.

Revenue mechanics are anchored on negotiated, multi-year supply contracts with committed purchasing volumes rather than transactional sales. Pricing is not publicly disclosed and contracts are individually negotiated; current reported revenue is negligible as the company is at the pilot-to-commercial transition, with the first material revenue inflection expected once AlphaOne commences commercial production. The company is led by CEO Jasper Kurth (formerly Bayer Radiology Nordic), CFO/COO Brede Ellingsæter, CTO Prof. Sindre Hassfjell, and Chairman John Andersen (CEO of founding shareholder Scatec Innovation AS, which holds 22.81% of shares as of 31 May 2026).

Short descriptiontext

Thor Medical ASA is a Norwegian biopharmaceutical company that produces alpha-emitting radioisotopes (Thorium-228, Radium-224, Lead-212) for targeted alpha cancer therapy using a proprietary, reactor-free thorium separation process, supplying radiopharmaceutical developers and CDMOs through multi-year master supply agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
alpha-emitting radioisotopes, medical isotope manufacturing, targeted alpha therapy, radiopharmaceutical supply, thorium-based isotope production
Industry3 codes
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAH
Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Irradiation Apparatus Manufacturing334517
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Isotope product sales
TypeHardware Sales
Description

Sale of alpha-emitting radioisotopes (Thorium-228, Radium-224, Lead-212) produced at the Herøya facility. Pilot operations since 2024 with product sales and delivery to leading industry players since 2025. Commercial-scale supply commences from AlphaOne in Q3 2026.

thormedical.com
2Multi-year master supply agreements
TypeSubscription Recurring
Description

Long-term, multi-year supply agreements with radiopharmaceutical developers, providing committed purchasing volumes. Example: expanded strategic master supply agreement with AdvanCell raising total purchasing commitment to NOK 150 million over five years. RadioMedix agreement also five years starting 2026.

thormedical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales
Pricing details1 tier
1Multi-year supply contracts with committed purchasing volumes (e.g., AdvanCell NOK 150M over 5 years)
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing negotiated individually per supply agreement; AdvanCell commitment of NOK 150M over 5 years for Thorium-228 supply.

thormedical.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1AlphaOne
Description

First commercial-scale production facility for alpha emitters, under development at Herøya Industrial Park in Norway; designed to scale production for commercial isotope delivery worldwide.

thormedical.com
Core offering1 text field

Thor Medical produces and supplies medical alpha-emitting radioisotopes — Thorium-228 (Th-228), Radium-224 (Ra-224), and Lead-212 (Pb-212) — for use in targeted alpha therapy for cancer. The isotopes are manufactured at the company's pilot facility and forthcoming AlphaOne commercial plant at Herøya Industrial Park in Norway using a proprietary process that separates naturally occurring radioactive decay products from thorium (Th-232) without requiring irradiation in nuclear reactors or charged particle accelerators. Products are sold to radiopharmaceutical developers, biotech firms, and CDMOs through multi-year master supply agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Thorium-228 supply to AdvanCell increased by 50% under expanded strategic master supply agreement
+4 more records
Product overview1 text field

Thor Medical operates a single, vertically integrated production platform centered on a proprietary thorium-based process for manufacturing medical alpha-particle emitters used in targeted alpha therapy for cancer. The platform yields a portfolio of named isotope products — Thorium-228 (Th-228) as the parent feedstock, and the medical alpha-emitters Radium-224 (Ra-224) and Lead-212 (Pb-212) — all produced from the same underlying process and supplied to radiopharmaceutical developers. Production is anchored by the Pilot Production Facility at Herøya Industrial Park (operational since 2024) and the larger AlphaOne Production Facility (mechanical completion in April 2026, production start planned for Q3 2026), which together move the offering from pilot-scale qualification to scaled commercial supply.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierStrategic European Channel PartnerTypeStrategic or Co-development PartnerAnnounced on2026-05-29
Description

Thor Medical signed a collaboration and supply agreement with Minerva Imaging, a Scandinavian integrated CRO and CDMO specialized in targeted radionuclide therapies. Under the agreement, Thor Medical will supply Lead-212 (Pb-212) to Minerva Imaging for preclinical use in radiopharmaceutical R&D. The collaboration aims to support broader access to lead-212-based therapies in the European market.

Strategic tierFlagship Global Channel PartnerTypeStrategic or Co-development PartnerAnnounced on2026-05-28
Description

Thor Medical signed a collaboration and supply agreement with Eckert & Ziegler SE, a world-leading specialist in isotope-related components, equipment and services for nuclear medicine and radiation therapy. Under the agreement, Thor Medical will initially supply Lead-212 (Pb-212) to Eckert & Ziegler for preclinical R&D. Both companies will also explore how to further integrate their complementary capabilities in isotope production and radiopharmaceutical manufacturing, with the aim of scaling up production capacity over time.

3Node Pharma
Strategic tierCommercial PartnerTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

Thor Medical entered a multiyear frame agreement with Node Pharma, a Norwegian radiopharmaceutical company, for the supply of Radium-224 (Ra-224) and Lead-212 (Pb-212) for preclinical use. The agreement follows successful product sample deliveries from Thor Medical's pilot facility at Herøya Industrial Park and supports Node Pharma's development pipeline for alpha-emitting therapies.

thormedical.com
Strategic tierCore Commercial PartnerTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Thor Medical ASA and RadioMedix, Inc. entered into a five-year supply agreement for Thorium-228 starting in 2026. The agreement supports the development and commercialization of targeted alpha therapies for cancer, leveraging Thor Medical's environmentally friendly alpha-emitters.

5Nuclithera
Strategic tierCommercial PartnerTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

Thor Medical entered a supply agreement with Nuclithera for Thorium-228 to support the customer's radiopharmaceutical development pipeline.

tradingview.com
Strategic tierFlagship / Core Commercial PartnerTypeStrategic or Co-development PartnerAnnounced on2025-08-04
Description

Thor Medical and AdvanCell expanded their strategic master supply agreement for Thorium-228, increasing supply by 50% and raising the total purchasing commitment from NOK 100 million to NOK 150 million over five years. Capacity expansion enabled by a planned 40% increase at Thor Medical's AlphaOne plant, financed by proceeds from its June 2025 capital raise. AdvanCell is accelerating its Lead-212 PSMA clinical program and has a strategic collaboration with Lilly announced in February 2025, both of which are expected to drive further demand for Thorium-228.

7Scatec Innovation AS
Strategic tierFounding Shareholder — Strategic AnchorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Scatec Innovation AS is the founding shareholder of Thor Medical (founded in 2017) and remains the largest shareholder with 22.81% ownership (as of 31 May 2026). Mr. John Andersen, CEO of Scatec Innovation AS, serves as Chairman of the Board of Thor Medical. Scatec Innovation AS is also the former employer of Thor Medical's CFO Brede Ellingsæter.

thormedical.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based medical radioisotope producer supplying therapeutic and diagnostic isotopes (e.g., Mo-99, Cu-64, Cu-67, Ga-68) to radiopharmaceutical developers. Directly comparable to Thor Medical as a non-reactor-based isotope producer supplying the radiopharma supply chain.

TypeDirect peer
Description

Global nuclear medicine company producing radiopharmaceutical isotopes and finished radiopharmaceuticals for SPECT, PET, and therapy. Operates large-scale isotope production facilities and serves the same downstream radiopharma developer customer base as Thor Medical.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing targeted alpha therapies using Pb-212. Highly comparable: directly overlaps in the alpha-emitter (Pb-212) space, and Thor Medical's CTO Prof. Sindre Hassfjell previously served as Director of generator development at ARTBIO.

TypeDirect peer
Description

German radiopharmaceutical group producing medical radioisotopes (Lu-177, Y-90, Ac-225 candidates) and developing targeted radionuclide therapies. Closely comparable as a vertically integrated medical isotope producer and radiotherapeutic developer serving a similar customer base.

TypeDirect peer
Description

Australian clinical-stage radiopharmaceutical company developing Pb-212-based targeted alpha therapies (notably PSMA program with Lilly partnership). Anchored on Thorium-228 sourced from Thor Medical; directly comparable as a downstream customer-developer in the same alpha-emitter value chain.

TypeBroad incumbent
Description

World-leading specialist in isotope-related components, equipment and services for nuclear medicine and radiation therapy. Also a commercial channel partner for Thor Medical (supply agreement for Pb-212), making it both a peer (broad incumbent in isotope production) and a customer.

TypeEmerging player
Description

Australian clinical-stage radiopharmaceutical company developing targeted radiopharmaceuticals using Cu-64/Cu-67 and other isotopes for cancer therapy. Comparable as an emerging player in the therapeutic radiopharmaceutical space, and Thomas Ramdahl (Thor Medical board member) also sits on Clarity's board.

TypeBroad incumbent
Description

Commercial-stage radiopharmaceutical company with approved imaging agents and an expanding therapeutic pipeline. Broad incumbent operating across multiple isotopes and indications; relevant comparable for scale, distribution model, and radiopharma market dynamics.

TypeBroad incumbent
Description

US radiopharmaceutical leader with approved diagnostic and therapeutic agents (e.g., Pylarify, Definity). Broad incumbent providing a benchmark for radiopharmaceutical commercial economics, sales channels, and isotope sourcing strategy relevant to Thor Medical's downstream customers.

TypeBroad incumbent
Description

Global pharma incumbent with significant radiopharmaceutical and alpha-emitter exposure through the acquisition of Algeta ASA (Xofigo, Ra-223). Relevant comparable as a broad incumbent in therapeutic radiopharmaceuticals; Thor Medical's CEO Jasper Kurth was previously GM of Bayer's Nordic Radiology division.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Thor Medical

Thor Medical ASA is a Norwegian biopharmaceutical company that produces alpha-emitting radioisotopes (Thorium-228, Radium-224, Lead-212) for targeted alpha cancer therapy using a proprietary, reactor-free thorium separation process, supplying radiopharmaceutical developers and CDMOs through multi-year master supply agreements.

What Thor Medical does

Thor Medical ASA is a Norwegian biopharmaceutical company founded in 2017 and listed on the Oslo Stock Exchange (ticker TRMED) that produces alpha-emitting radioisotopes — Thorium-228, Radium-224 and Lead-212 — for use in targeted alpha therapy for haematological and other cancers. Its core technology is a proprietary, trade-secret-protected separation process that extracts naturally occurring radioactive decay products from thorium-232 without requiring irradiation in nuclear reactors or charged particle accelerators, and uses a closed-loop reprocessing system that reuses all chemicals and radioactive materials while producing minimal waste. The platform effectively turns a single source material (thorium, with a 14 billion year half-life) into multiple medically relevant alpha emitters, two of which — Ra-224 and Pb-212 — are leading candidates for next-generation cancer therapy because alpha particles destroy cancer cells within less than 0.1 mm of range, enabling highly selective treatment of micrometastases.

The company operates a pilot production facility at Herøya Industrial Park in Norway, which has been producing alpha-emitting isotopes since 2024 and supplying them for research and early customer deliveries since 2025. Its first commercial-scale facility, AlphaOne, reached mechanical completion on time and on budget in April 2026 and is targeting production start in Q3 2026, with a planned 40% capacity expansion financed by a June 2025 capital raise. Thor Medical sells isotopes directly to radiopharmaceutical developers and biotech companies through multi-year master supply agreements — AdvanCell (NOK 150M over 5 years, expanded August 2025), RadioMedix (5-year supply from 2026), Nuclithera and Node Pharma — and to radiopharmaceutical CDMOs and integrated service providers such as Minerva Imaging and Eckert & Ziegler SE, which act as channel partners embedding Thor Medical's isotopes within broader development and manufacturing platforms. Customer segments are vertically aligned (radiopharmaceutical developers, CDMOs, and research/early-stage clinical developers), with the addressable radiotherapeutics market expected to reach approximately USD 20 billion by 2030.

Revenue mechanics are anchored on negotiated, multi-year supply contracts with committed purchasing volumes rather than transactional sales. Pricing is not publicly disclosed and contracts are individually negotiated; current reported revenue is negligible as the company is at the pilot-to-commercial transition, with the first material revenue inflection expected once AlphaOne commences commercial production. The company is led by CEO Jasper Kurth (formerly Bayer Radiology Nordic), CFO/COO Brede Ellingsæter, CTO Prof. Sindre Hassfjell, and Chairman John Andersen (CEO of founding shareholder Scatec Innovation AS, which holds 22.81% of shares as of 31 May 2026).

Thor Medical firmographics

Firmographics
Name
Thor Medical
Legal name
Thor Medical ASA
Website
https://thormedical.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Thor Medical ASA is a Norwegian biopharmaceutical company that produces alpha-emitting radioisotopes (Thorium-228, Radium-224, Lead-212) for targeted alpha cancer therapy using a proprietary, reactor-free thorium separation process, supplying radiopharmaceutical developers and CDMOs through multi-year master supply agreements.
Ownership category
akta.pro rank

Thor Medical industry classification

Industry
NAICS
Irradiation Apparatus Manufacturing (334517)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAH
Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Alpha-emitting radioisotopes
  • Medical isotope manufacturing
  • Targeted alpha therapy
  • Radiopharmaceutical supply
  • Thorium-based isotope production

Where Thor Medical is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices2 records

Markets served

Thor Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Infrastructure, Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Isotope product sales: Sale of alpha-emitting radioisotopes (Thorium-228, Radium-224, Lead-212) produced at the Herøya facility. Pilot operations since 2024 with product sales and delivery to leading industry players since 2025. Commercial-scale supply commences from AlphaOne in Q3 2026.
  2. Multi-year master supply agreements: Long-term, multi-year supply agreements with radiopharmaceutical developers, providing committed purchasing volumes. Example: expanded strategic master supply agreement with AdvanCell raising total purchasing commitment to NOK 150 million over five years. RadioMedix agreement also five years starting 2026.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMulti-year supply contracts with committed purchasing volumes (e.g., AdvanCell NOK 150M over 5 years)

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Thor Medical product offering

Product offering

Core offering

Thor Medical produces and supplies medical alpha-emitting radioisotopes — Thorium-228 (Th-228), Radium-224 (Ra-224), and Lead-212 (Pb-212) — for use in targeted alpha therapy for cancer. The isotopes are manufactured at the company's pilot facility and forthcoming AlphaOne commercial plant at Herøya Industrial Park in Norway using a proprietary process that separates naturally occurring radioactive decay products from thorium (Th-232) without requiring irradiation in nuclear reactors or charged particle accelerators. Products are sold to radiopharmaceutical developers, biotech firms, and CDMOs through multi-year master supply agreements.

Product overview

Thor Medical operates a single, vertically integrated production platform centered on a proprietary thorium-based process for manufacturing medical alpha-particle emitters used in targeted alpha therapy for cancer. The platform yields a portfolio of named isotope products — Thorium-228 (Th-228) as the parent feedstock, and the medical alpha-emitters Radium-224 (Ra-224) and Lead-212 (Pb-212) — all produced from the same underlying process and supplied to radiopharmaceutical developers. Production is anchored by the Pilot Production Facility at Herøya Industrial Park (operational since 2024) and the larger AlphaOne Production Facility (mechanical completion in April 2026, production start planned for Q3 2026), which together move the offering from pilot-scale qualification to scaled commercial supply.

Differentiator

Problem solved

Functional benefit

Brands

  • AlphaOne: First commercial-scale production facility for alpha emitters, under development at Herøya Industrial Park in Norway; designed to scale production for commercial isotope delivery worldwide.

Quantifiable outcome

  • Thorium-228 supply to AdvanCell increased by 50% under expanded strategic master supply agreement
  • +4 more outcomes

Companies that use Thor Medical

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Thor Medical technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Thor Medical partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered strategic european channel partner, flagship global channel partner, commercial partner, core commercial partner, flagship / core commercial partner and founding shareholder — strategic anchor.

  • Minerva Imagingstrategic european channel partnerStrategic or Co-development Partner · 29 May 2026Thor Medical signed a collaboration and supply agreement with Minerva Imaging, a Scandinavian integrated CRO and CDMO specialized in targeted radionuclide therapies. Under the agreement, Thor Medical will supply Lead-212 (Pb-212) to Minerva Imaging for preclinical use in radiopharmaceutical R&D. The collaboration aims to support broader access to lead-212-based therapies in the European market.
  • Eckert & Zieglerflagship global channel partnerStrategic or Co-development Partner · 28 May 2026Thor Medical signed a collaboration and supply agreement with Eckert & Ziegler SE, a world-leading specialist in isotope-related components, equipment and services for nuclear medicine and radiation therapy. Under the agreement, Thor Medical will initially supply Lead-212 (Pb-212) to Eckert & Ziegler for preclinical R&D. Both companies will also explore how to further integrate their complementary capabilities in isotope production and radiopharmaceutical manufacturing, with the aim of scaling up production capacity over time.
  • Node Pharmacommercial partnerStrategic or Co-development Partner · 26 March 2026Thor Medical entered a multiyear frame agreement with Node Pharma, a Norwegian radiopharmaceutical company, for the supply of Radium-224 (Ra-224) and Lead-212 (Pb-212) for preclinical use. The agreement follows successful product sample deliveries from Thor Medical's pilot facility at Herøya Industrial Park and supports Node Pharma's development pipeline for alpha-emitting therapies.
  • RadioMedixcore commercial partnerStrategic or Co-development Partner · 4 December 2025Thor Medical ASA and RadioMedix, Inc. entered into a five-year supply agreement for Thorium-228 starting in 2026. The agreement supports the development and commercialization of targeted alpha therapies for cancer, leveraging Thor Medical's environmentally friendly alpha-emitters.
  • Nuclitheracommercial partnerStrategic or Co-development Partner · 20 November 2025Thor Medical entered a supply agreement with Nuclithera for Thorium-228 to support the customer's radiopharmaceutical development pipeline.
  • AdvanCellflagship / core commercial partnerStrategic or Co-development Partner · 4 August 2025Thor Medical and AdvanCell expanded their strategic master supply agreement for Thorium-228, increasing supply by 50% and raising the total purchasing commitment from NOK 100 million to NOK 150 million over five years. Capacity expansion enabled by a planned 40% increase at Thor Medical's AlphaOne plant, financed by proceeds from its June 2025 capital raise. AdvanCell is accelerating its Lead-212 PSMA clinical program and has a strategic collaboration with Lilly announced in February 2025, both of which are expected to drive further demand for Thorium-228.
  • Scatec Innovation ASfounding shareholder — strategic anchorStrategic or Co-development Partner · 1 January 2017Scatec Innovation AS is the founding shareholder of Thor Medical (founded in 2017) and remains the largest shareholder with 22.81% ownership (as of 31 May 2026). Mr. John Andersen, CEO of Scatec Innovation AS, serves as Chairman of the Board of Thor Medical. Scatec Innovation AS is also the former employer of Thor Medical's CFO Brede Ellingsæter.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Thor Medical competitors and assessment

Company assessment

Direct peers

  • NorthStar Medical Radioisotopes: US-based medical radioisotope producer supplying therapeutic and diagnostic isotopes (e.g., Mo-99, Cu-64, Cu-67, Ga-68) to radiopharmaceutical developers. Directly comparable to Thor Medical as a non-reactor-based isotope producer supplying the radiopharma supply chain.
  • Curium Pharma: Global nuclear medicine company producing radiopharmaceutical isotopes and finished radiopharmaceuticals for SPECT, PET, and therapy. Operates large-scale isotope production facilities and serves the same downstream radiopharma developer customer base as Thor Medical.
  • ARTBIO: Clinical-stage radiopharmaceutical company developing targeted alpha therapies using Pb-212. Highly comparable: directly overlaps in the alpha-emitter (Pb-212) space, and Thor Medical's CTO Prof. Sindre Hassfjell previously served as Director of generator development at ARTBIO.
  • ITM Isotope Technologies Munich: German radiopharmaceutical group producing medical radioisotopes (Lu-177, Y-90, Ac-225 candidates) and developing targeted radionuclide therapies. Closely comparable as a vertically integrated medical isotope producer and radiotherapeutic developer serving a similar customer base.
  • AdvanCell: Australian clinical-stage radiopharmaceutical company developing Pb-212-based targeted alpha therapies (notably PSMA program with Lilly partnership). Anchored on Thorium-228 sourced from Thor Medical; directly comparable as a downstream customer-developer in the same alpha-emitter value chain.

Broad incumbents

  • Eckert & Ziegler SE: World-leading specialist in isotope-related components, equipment and services for nuclear medicine and radiation therapy. Also a commercial channel partner for Thor Medical (supply agreement for Pb-212), making it both a peer (broad incumbent in isotope production) and a customer.
  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with approved imaging agents and an expanding therapeutic pipeline. Broad incumbent operating across multiple isotopes and indications; relevant comparable for scale, distribution model, and radiopharma market dynamics.
  • Lantheus Holdings: US radiopharmaceutical leader with approved diagnostic and therapeutic agents (e.g., Pylarify, Definity). Broad incumbent providing a benchmark for radiopharmaceutical commercial economics, sales channels, and isotope sourcing strategy relevant to Thor Medical's downstream customers.
  • Bayer AG (Radiology / Xofigo): Global pharma incumbent with significant radiopharmaceutical and alpha-emitter exposure through the acquisition of Algeta ASA (Xofigo, Ra-223). Relevant comparable as a broad incumbent in therapeutic radiopharmaceuticals; Thor Medical's CEO Jasper Kurth was previously GM of Bayer's Nordic Radiology division.

Emerging players

  • Clarity Pharmaceuticals: Australian clinical-stage radiopharmaceutical company developing targeted radiopharmaceuticals using Cu-64/Cu-67 and other isotopes for cancer therapy. Comparable as an emerging player in the therapeutic radiopharmaceutical space, and Thomas Ramdahl (Thor Medical board member) also sits on Clarity's board.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Thor Medical social profiles

Digital presence

Thor Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Thor Medical leadership team

Management profile

Number of profiles

Thor Medical funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Thor Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thor Medical

What does Thor Medical do?

Thor Medical produces and supplies medical alpha-emitting radioisotopes — Thorium-228 (Th-228), Radium-224 (Ra-224), and Lead-212 (Pb-212) — for use in targeted alpha therapy for cancer. The isotopes are manufactured at the company's pilot facility and forthcoming AlphaOne commercial plant at Herøya Industrial Park in Norway using a proprietary process that separates naturally occurring radioactive decay products from thorium (Th-232) without requiring irradiation in nuclear reactors or charged particle accelerators. Products are sold to radiopharmaceutical developers, biotech firms, and CDMOs through multi-year master supply agreements.

Is Thor Medical a public or private company?

Thor Medical is a public company. It is currently operating.

When was Thor Medical founded?

Thor Medical was founded in 2017. It employs 11 to 50 people.

Where is Thor Medical based?

Thor Medical is headquartered in Oslo, Norway, in the Europe region.

How does Thor Medical make money?

Two revenue lines are on record. Isotope product sales are the primary driver. The others are multi-year master supply agreements.

Who are Thor Medical's main competitors?

Direct peers on record are NorthStar Medical Radioisotopes, Curium Pharma, ARTBIO, ITM Isotope Technologies Munich and AdvanCell. Broad incumbents are Eckert & Ziegler SE, Telix Pharmaceuticals, Lantheus Holdings and Bayer AG (Radiology / Xofigo). Clarity Pharmaceuticals is listed as an emerging player.

Does Thor Medical have an API?

No public API is recorded for Thor Medical.

What industry is Thor Medical in?

Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 334517 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
E24Biotekaksje faller kraftig på Oslo BørsOslo Børs fell 0.17% on Friday, with Equinor and Telenor down and Frontline up. Thor Medical raised 300 million NOK, and Norwegian reported 2.5 million passengers in August, up 4%.E24Oslo Børs stiger fra startOslo Børs rose 0.57% at 12:30, with the main index up after a record close. Frontline reported record Q2 earnings of $659 million, while Thor Medical fell sharply after a Q2 loss. Oil prices held near $88 per barrel.AInvestThor Medical: Brede will remain CFO until successor takes up position, before transitioning fully to his role as chief operating officerThor Medical's CFO, Brede, will remain in that role until a successor assumes the position, after which he will fully transition to chief operating officer. The company has not disclosed the successor's name or timeline.ThormedicalThor Medical and AdvanCell expand strategic supply agreement for Thorium-228Thor Medical ASA has expanded its strategic master supply agreement with AdvanCell, increasing Thorium-228 supply by 50% and raising the total purchasing commitment from NOK 100 million to NOK 150 million over five years. The capacity expansion is enabled by a planned 40% increase at Thor Medical's AlphaOne plant, financed by proceeds from its June 2025 capital raise. AdvanCell is accelerating its Lead-212 PSMA clinical program and has a strategic collaboration with Lilly announced in February 2025, both of which are expected to drive further demand for Thorium-228.FinansavisenThor Medical ASA: Private placement and retail offering through PrimaryBid successfully completedThor Medical completed a private placement and retail offering, raising NOK 75 million and NOK 11.4 million respectively. The company allocated 30 million shares in the private placement and 4.58 million in the retail offering, with net proceeds funding a 40% capacity expansion at AlphaOne. Settlement is expected on 23 June 2025.ThormedicalThor Medical ASA: Key information relating to potential subsequent offeringThor Medical ASA announced on 18 June 2025 that it is considering a subsequent share offering of up to 4,000,000 new shares with subscription rights. The subscription price is NOK 2.50, and the offering is subject to corporate resolutions and a Norwegian prospectus registration.news.cision.comNordic Nanovector ASA announces that Ludvik Sandnes has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO)Nordic Nanovector appointed Ludvik Sandnes as interim CEO and CFO effective 1 February 2023, replacing Malene Brondberg. The company's uncommitted net cash is approximately NOK 60m, and it will report Q4 2022 and full-year results on 28 February.FierceBiotechNordic Nanovector pulls the plug on troubled Paradigme trial, moves for restructuringNordic Nanovector discontinued its phase 2b trial for Betalutin, an anti-CD37 antibody, after failing to enroll patients and poor response rates. The company announced restructuring and cost-cutting measures, with details to be disclosed in the August 31 earnings report. It will explore partnerships and other CD37 assets.news.cision.comNordic Nanovector ASA: The Annual General Meeting heldNordic Nanovector's annual general meeting was held on 28 April 2022 in Oslo, Norway, and all proposals were resolved as presented. The company's lead candidate, Betalutin, is a CD37-targeting radioimmunotherapy for non-Hodgkin's lymphoma, with a market forecast of nearly $27 billion by 2029.news.cision.comNordic Nanovector ASA - Share capital increase registeredNordic Nanovector's share capital increase from its subsequent offering was registered on 22 March 2022, adding NOK 11,420 via 57,100 new shares at NOK 14 each. The company's issued share capital is now NOK 23,198,524.60, divided into 115,992,623 shares. The new shares are admitted to listing on the Oslo Stock Exchange.